Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$304M |
| 2 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$189M |
| 3 |
AbbVie
ABBV
|
+$185M |
| 4 |
JPMorgan Ultra-Short Income ETF
JPST
|
+$176M |
| 5 |
iShares US Treasury Bond ETF
GOVT
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$430M |
| 2 |
Vanguard High Dividend Yield ETF
VYM
|
+$400M |
| 3 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$374M |
| 4 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$361M |
| 5 |
Invesco Actively Managed Exch-Traded Commodity Fd Tr Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF
PDBC
|
+$154M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.95% |
| 2 | Healthcare | 12.56% |
| 3 | Financials | 11.62% |
| 4 | Consumer Discretionary | 10.14% |
| 5 | Industrials | 9.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3076
Bioventus
BVS
$893M
| $479K | ﹤0.01% |
165,629
-70,716
| -30% | -$136K |
|
3077
CRH
CRH
$64.1B
| $478K | ﹤0.01% |
8,579
+3,573
| +71% | +$178K |
|
3078
ThredUp
TDUP
$757M
| $478K | ﹤0.01% |
195,845
+27,310
| +16% | +$71.5K |
|
3079
Primis Financial Corp
FRST
$396M
| $477K | ﹤0.01% |
56,616
-5,178
| -8% | -$43.3K |
|
|
CCRD
3080
DELISTED
CoreCard
CCRD
| $476K | ﹤0.01% |
18,769
-2,049
| -10% | -$52.9K |
|
3081
Tredegar Corp
TG
$262M
| $474K | ﹤0.01% |
71,132
-5,716
| -7% | -$45.3K |
|
|
ITI
3082
DELISTED
Iteris, Inc.
ITI
| $472K | ﹤0.01% |
119,272
+97,633
| +451% | +$436K |
|
3083
Altimmune
ALT
$580M
| $471K | ﹤0.01% |
133,395
+112,999
| +554% | +$507K |
|
3084
Alico
ALCO
$283M
| $471K | ﹤0.01% |
18,485
+374
| +2% | +$9.1K |
|
3085
Cadiz
CDZI
$264M
| $469K | ﹤0.01% |
115,582
+99,760
| +631% | +$440K |
|
3086
Core Molding Technologies
CMT
$200M
| $469K | ﹤0.01% |
+20,596
| New | +$400K |
|
3087
Quantum-Si Incorporated
QSI
$157M
| $468K | ﹤0.01% |
261,577
+23,349
| +10% | +$36.6K |
|
3088
C&F Financial
CFFI
$272M
| $468K | ﹤0.01% |
+8,710
| New | +$461K |
|
|
VOXX
3089
DELISTED
VOXX International Corporation Class A
VOXX
| $465K | ﹤0.01% |
+37,294
| New | +$441K |
|
3090
UroGen Pharma
URGN
$2B
| $463K | ﹤0.01% |
+44,724
| New | +$493K |
|
3091
Oportun Financial
OPRT
$259M
| $462K | ﹤0.01% |
77,344
-63,540
| -45% | -$312K |
|
3092
Zevra Therapeutics
ZVRA
$570M
| $461K | ﹤0.01% |
90,432
+79,293
| +712% | +$427K |
|
|
PAMT
3093
PAMT Corp
PAMT
$347M
| $461K | ﹤0.01% |
17,204
-827
| -5% | -$21.1K |
|
|
BCOV
3094
DELISTED
Brightcove, Inc.
BCOV
| $459K | ﹤0.01% |
114,500
+4,104
| +4% | +$16.6K |
|
3095
National Bankshares
NKSH
$253M
| $459K | ﹤0.01% |
+15,718
| New | +$468K |
|
|
GRTS
3096
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $458K | ﹤0.01% |
234,649
+200,640
| +590% | +$470K |
|
|
JBIO
3097
Jade Biosciences
JBIO
$1.22B
| $457K | ﹤0.01% |
762
+58
| +8% | +$37.1K |
|
3098
Weyco Group
WEYS
$377M
| $457K | ﹤0.01% |
17,125
+814
| +5% | +$21.8K |
|
3099
Capital Bancorp
CBNK
$603M
| $457K | ﹤0.01% |
25,241
+1,679
| +7% | +$28.7K |
|
3100
The ONE Group
STKS
$56.5M
| $456K | ﹤0.01% |
62,260
-1,076
| -2% | -$8.17K |
|
Similar funds
Charles Schwab's Q2 2023 Portfolio in Review
As of Q2 2023, Charles Schwab held 3,760 positions worth $350B, up 6.4% from $329B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Charles Schwab's Q2 2023 filing shows 210 new, 2,215 increased, 1,001 reduced and 151 closed positions. Its largest new stake was iShares US Treasury Bond ETF: 7,510,883 shares worth $172M. The largest sale was Broadcom, an estimated $430M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Healthcare and Financials.
- Charles Schwab's largest Q2 2023 buy was iShares US Treasury Bond ETF: 7,510,883 shares worth $172M.
- Charles Schwab added most to State Street Technology Select Sector SPDR ETF in Q2 2023, an estimated $304M increase.
- Charles Schwab's biggest Q2 2023 reduction was Broadcom, cutting an estimated $430M.
- Charles Schwab fully exited iShares 0-1 Year Treasury Bond ETF in Q2 2023, selling an estimated $361M.
- Charles Schwab's ten largest holdings make up 19% of its $350B portfolio in Q2 2023.
- Charles Schwab opened 210 new positions and closed 151 in Q2 2023.
- Charles Schwab's portfolio value rose 6.4% quarter-over-quarter to $350B.
Based on Charles Schwab's 13F filing for Q2 2023, filed 10 Aug 2023.